Vanguard Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,206,814 shares of SUPN stock, worth $168 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,206,814
Previous 6,214,731
0.13%
Holding current value
$168 Million
Previous $180 Million
17.71%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding SUPN
# of Institutions
260Shares Held
57.3MCall Options Held
84.1KPut Options Held
61.2K-
Black Rock Inc. New York, NY10.4MShares$281 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY3.57MShares$96.9 Million1.66% of portfolio
-
Macquarie Group LTD Australia, C32.67MShares$72.4 Million0.1% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.56MShares$69.3 Million0.02% of portfolio
-
State Street Corp Boston, MA2.04MShares$55.3 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.45B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...